TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent form~* Age 18-75 years~* Able to adhere to the study visit schedule and other protocol requirements~* Patients with multiple myeloma who have received high-dose therapy and autologous stem cell transplantation as first-line therapy within the last 90 - 120 days and have not shown progressive disease afterwards.~* Patients may have received up to 6 cycles of prior induction therapy and up to 2 cycles of prior mobilisation chemotherapy. A bortezomib or thalidomide induction therapy is allowed. Patients may also have received prior radiation therapy~* Measurable levels of myeloma paraprotein in serum (\>0.5 g/dL) or urine (\>0.2 g/24hours) or measurable free light chains (FLC) in serum (\>50 mg/l) with an abnormal FLC ratio must be documented at the time of first diagnosis.~* ECOG performance status = 2 at study entry~* Laboratory and functional test results within these ranges:~  * ANC ≥ 1,000/μL~ * Platelet count ≥ 100,000/μL~ * Total bilirubin 2.5 mg/dL~ * AST (SGOT) and ALT (SGPT) 3 x ULN~ * Patients with impaired renal function can be included~* The patient must be able to adhere to the pregnancy precautions~* Disease free of prior malignancies for 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast~Exclusion Criteria:~* Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form~* Pregnant or breast feeding females~* Any condition or laboratory abnormality which places the subject at an unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study~* Known allergic/hypersensitivity reaction to thalidomide, lenalidomide or any components of the treatment~* Any cutaneous grade ≥ 3 adverse reaction (for example desquamating rash) while taking thalidomide or similar drugs~* Any prior use of lenalidomide~* Known positive for HIV or active infectious hepatitis, type A, B or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 25 mg lenalidomide
- 2 (Type: EXPERIMENTAL): 5 mg lenalidomide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaporization as a Smokeless Cannabis Delivery System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 21-45 years Current history use of marijuana. Subjects must have smoked marijuana within the past 30 days but an amount totaling less than 10 marijuana cigarettes or the equivalent.~All men and women in this study must agree to use adequate birth control during the study. Acceptable barrier birth control methods are a male condom, female condom, diaphragm, or intra-uterine (IUD).~All women of reproductive potential (who have not reached menopause or undergone hysterectomy, oophorectomy,or tubal ligation) must have a negative urine B-HCG pregnancy test performed 48 hours before initiating the protocol-specified medication.~Able to understand and follow the instructions of the investigator and research personnel.~Able and willing to provide informed consent.~Exclusion Criteria:~* Severe coronary artery disease, uncontrolled hypertension, cardiac ventricular conduction abnormalities, or orthostatic mean blood pressure drop greater than 24mm/Hg, severe chronic obstructive pulmonary disease.~History of renal or hepatic failure. Evidence of hepatic, hematological or renal dysfunction based on judgement of physician.~Active substance abuse. Marijuana dependence as defined in DSM-IV code#304.30. Any psychiatric dysfunction that would, in the opinion of the study investigator, interfere with a participant's ability to comply with the study protocol.~Use of tobacco within the past 30 days. Subjects taking medications which may be vulnerable to drug-drug interactions such as those metabolized by the cytochrome P450 enzyme system.~Blood donation in the past 30 days. Use of smoked marijuana within 48 hours of GCRC admission. Women who are pregnant or breast-feeding may not take part in this study. Unable to read or speak English.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Self-identified Black, African or African American women of ≥ 18 years of age with proven diagnosis of advanced adenocarcinoma of the breast (locoregionally recurrent or metastatic disease)~2. ER-positive and/or PgR-positive tumor based on local laboratory results~3. HER2-negative breast cancer based on local laboratory results (test to be used as per local practice)~4. Patients must be appropriate candidates for letrozole or fulvestrant therapy~5. Eastern Cooperative Oncology Group (ECOG) performance status 0-2~6. Adequate bone marrow function:~   * Absolute Neutrophil Count (ANC) ≥ 1,000/mm3 (1.0 x 109/L);~  * Platelets ≥100,000/mm3 (100 x 109/L);~  * Hemoglobin ≥9 g/dL (90 g/L).~Exclusion Criteria:~1. Current use of food or drugs known to be potent inhibitors or inducers of CYP3A4~2. Active uncontrolled or symptomatic brain metastases. Previously treated and clinically stable, as per Investigator's judgment, brain metastases are permitted.~3. Previous CDK4/6 inhibitor~   -

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Palbociclib + Letrozole or Fulvestrant (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Low Back Pain and Meditation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have a medical evaluation that demonstrates chronic low back pain that is evoked by lifting the legs. Existing medical records, per physician discretion and low back examinations will confirm diagnosis~* Participants must be between 18 and 65 years of age~* Participants must rate their daily chronic pain intensity at a 3 or higher on 0-10 visual analog scale~* Participants must have experienced their chronic low back pain for at least 3 months~* Participants must have no prior meditative experience~* Participants must be straight leg raise test positive~Exclusion Criteria:~* Participants must not be participating in any new (within 2 weeks prior or anytime after enrollment) pain management procedures during the study period~* Participants must not be taking opioids~* Participants must not be pregnant or nursing mothers~* Participants must have not had back surgery within the last year before their enrollment into the study~* Participants must have not had any other sensory or motor deficits that preclude participation in this study~* Participants must not have known anomalies of the central nervous system including: stroke, dementia, aneurysm, and a personal history of psychosis~* Participants must not have any known allergies to naloxone or similar drugs~* Participants must not have a history of syncope and/or fear of needles/blood

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Meditation (Type: EXPERIMENTAL): Subjects will participate in four sessions (20 min/session) of mindfulness training. Participants will be taught that perceived sensory events are momentary and fleeting and require no further evaluation.
- meditation (Type: EXPERIMENTAL): Subjects will participate in four sessions (20 min/session) of mindfulness training. Participants will be taught that perceived sensory events are momentary and fleeting and require no further evaluation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Yoga for Veterans With CLBP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has a VA primary care provider~* Diagnosis of chronic low back pain \> 6 months~* Willing to attend a yoga program or be assigned to delayed treatment with yoga~* Willing to complete 4 assessments~* English Literacy~* Has not begun new pain treatments or medications in the past month~* Willing to not change pain treatments (e.g., discontinue a treatment; increase medication dose) during the 12-week intervention period unless medically necessary~Exclusion Criteria:~* back surgery within the last 12 months~* back pain due to specific systemic problem (eg, lupus, scleroderma, fibromyalgia)~* morbid obesity (BMI \> 40)~* Significant sciatica or nerve compression \< 3 months or chronic lumbar radicular pain \> 3 months~* Unstable, serious coexisting medical illness (eg, CHF, cancer, COPD, morbid obesity; dementia)~* Unstable, serious psychiatric illness (e.g., unmanaged psychosis, active substance dependence)~* Insufficient data to rule out acute, metastatic disease, (unless primary care physician approves)~* Attended or practiced yoga \> 1x in the last 12 months~* Positive Romberg test (with or without sensory neuropathy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Yoga (Type: EXPERIMENTAL): The yoga intervention will consist of 2x weekly, 60-minute Hatha Yoga classes for 12 weeks, geared toward a CLBP population. Classes begin with a few minutes of simple seated breathing exercises. Depending on their mobility, participants can sit either on the floor or on a chair. This is followed by gentle warm-up stretches. Participants are then led through a series of standing postures, seated postures and floor postures. The difficulty of the poses will gradually increase over the duration of the 12 weeks, and appropriate modifications are offered to participants whenever needed. Deep and rhythmic breathing will be emphasized throughout. Each class will end with a supine resting pose.
- Delayed Treatment Control - Usual Care (Type: NO_INTERVENTION): Participants randomly assigned to this arm are allowed to continue all existing treatments. Participants and their primary care physician are asked to not change treatments unless medically necessary. participants are asked to not do yoga for 6 months. They are given free yoga and a yoga mat after 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with primary humoral immunodeficiency who have participated in the study ZLB04_009CR (NCT00419341), namely with a diagnosis of Common Variable Immunodeficiency (CVID) as defined by PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies) or X-linked Agammaglobulinemia (XLA) as defined by PAGID and ESID~* Women of childbearing potential must be using and agree to continue using medically approved contraception and must have a negative pregnancy test at screening~* Written informed consent~Exclusion Criteria:~* Ongoing serious bacterial infection at the time of screening~* Malignancies of lymphoid cells such as lymphocytic leukemia, Non-Hodgkin's lymphoma, and immunodeficiency with thymoma~* Hypoalbuminemia, protein-losing enteropathies, and any proteinuria (defined by total urine protein concentration \> 0.2 g/L)~* Other significant medical conditions that could increase the risk to the patient~* Females who are pregnant, breast-feeding or planning a pregnancy during the course of the study~* A positive result at screening on any of the following viral markers: Human immunodeficiency virus (HIV), Hepatitis C virus (HCV) or Hepatitis B virus (HBV)~* Aspartate aminotransferase (ASAT) or Alanine aminotransferase (ALAT) concentration \> 2.5 times Upper Normal Limit (UNL) at Completion Visit of study ZLB04_009CR (NCT00419341)~* Creatinine concentration \> 1.5 times UNL at Completion Visit of study ZLB04_009CR (NCT00419341)~* Participation in a study with an investigational product other than IgPro20 within 3 months prior to enrollment~* Evidence of uncooperative attitude~* Any condition that is likely to interfere with evaluation of the study drug or satisfactory conduct of the trial~* Subjects who are employees at the investigational site, relatives or spouse of the investigator

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IgPro20 (Type: EXPERIMENTAL): The IgPro20 dose will be the same as in the previous pivotal study ZLB04_009CR (NCT00419341) infused subcutaneously weekly or twice a week (in the latter case, half of a weekly dose will be used)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Sickle cell disease (HbSS or S/β0 thalassemia)~* ≥ 3 vaso-occlusive pain episodes in the year prior to enrollment~* Age ≥ 10 years~* Weight \> 30 kg~Exclusion Criteria:~* Creatine kinase (CK) \> UNL~* Total cholesterol \< 90 mg/dL, or triglycerides \<30mg/dL~* Renal dysfunction (Creatinine \> 1.5-fold UNL)~* Hepatic dysfunction (ALT \> 2-fold UNL)~* Treatment with drugs having known metabolic interactions with statins within the past 30 days~* Vaso-occlusive pain requiring hospitalization within past 30 days~* Red blood cell transfusion within the past 30 days~* Pregnancy/lactation~* Musculoskeletal disorder associated with an elevated CK level~* Past or present history of substance abuse (alcohol, cocaine, amphetamines, heroin)~* Chronic pain caused by avascular necrosis of the bone (AVN) or leg ulcers, and pain due to trauma or causes other than SCD.~* Major cognitive or neurological impairments that may hamper the ability to use the smartphone or complete the electronic pain diary in this study

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- simvastatin (Type: EXPERIMENTAL): Simvastatin (Zocor), 40mg tablet, 40mg orally once daily, for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Grass Pollen Subcutaneous Immunotherapy in Elderly Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* a positive skin prick test (SPT), were positive for specific immunoglobulin E (sIgE), and had positive nasal provocation tests (NPTs) with grass pollen mixture allergens~Exclusion Criteria:~* hypersensitivity to other allergens, bronchial asthma, non-allergic rhinitis (especially senile or vasomotor rhinitis) and severe non-stable diseases.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Patients active (Type: ACTIVE_COMPARATOR): Purethal Grass
- Patients placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Atorvastatin in Acute Stroke Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible patients were men and women over 18 years of age who had an acute ischemic stroke with a symptom time onset \< 48 hours~Exclusion Criteria:~* Patients with inflammatory or infectious diseases, cancer, hematological diseases and severe renal or liver failure, as well as those who were under treatment with anti-inflammatory were excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- early Atorvastatin treatment (Type: EXPERIMENTAL): Ischemic stroke patients treated with with atorvastatin 80 mg at admission until discharge
- no early treatment with atorvastatin (Type: NO_INTERVENTION): Ischemic stroke patients not treated with with atorvastatin 80 mg until discharge

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fentanyl Test in Children's Adenotonsillectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:meet all of the following~1. the American society of anesthesiologists (ASA) class Ⅰ \~ Ⅱ~2. the age of 3 \~ 7 years old~3. children who underwent selective adenotonsillectomy.~Exclusion Criteria:meet anyone of the following~1. craniofacial malformations~2. mental retardation~3. BMI \> 22 kg/m2~4. a history of bronchial asthma~5. a recent history of opioid use.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 7 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Simvastatin Therapy in Smith-Lemli-Opitz Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~All patients with biochemically proven SLOS will be considered for this study.~EXCLUSION CRITERIA:~Patients will be excluded if they cannot travel to the NIH because of their medical condition.~Age less than 4 and older than 18.~Weight less than 10 kg.~Developmental delay too severe to obtain adequate behavioral evaluation.~Severe behavioral problems that preclude proper physical and laboratory medicine evaluation.~SLOS severity score greater than 30.~No biochemical diagnosis of SLOS.~No molecular conformation of SLOS.~Residual fibroblasts enzymatic activity less than 10% of control value (cholesterol synthesis as a fraction of total sterol synthesis).~Dehydrocholesterol/cholesterol ratio greater than 1.0.~Renal insufficiency.~Contraindications for simvastatin use:~History of hypersensitivity to simvastatin or other statins.~Acute liver disease.~Persistent elevations of serum transaminase levels or persistent elevations of CPK.~Concomitant therapy with tetralol-class calcium channel blockers (such as mibefradil).~Pregnancy or lactation.~History of rhabdomyolysis or myopathy.~Concomitant therapy with other drugs associated with myopathy (such as gemfibrozil or other fibrates, niacin) or metabolism by the P450 isoform 3A4 system (such as cyclosporin, itraconazole, ketoconazole, macrolide antibiotics, or nefazodone (Serzone)).~Warfarin-type anticoagulant therapy.~Severe cataracts.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- OraPlus (Type: PLACEBO_COMPARATOR): None
- Simvastatin Susp (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Opioid Free Anesthesia on Outcome After DIEPflap Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: DIEPflap unilat or bilat woman between 18 and 60 years old-~Exclusion Criteria: none~* allergy to any of the drugs used in anesthesia

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- opioid free anesthesia (OFA) (Type: None): The method of reaching OFA: Dexmedetomidine was given in a first loading dose 15 minutes before induction, a second loading dose at induction followed by an infusion for maintenance. Lidocaine is given as a loading dose at induction followed by infusion for maintenance. A Ketamine loading dose is given at induction with an extra bolus before incision followed by an infusion.
- opioid anesthesia (OA) (Type: None): OA was induced with sufentanil and continued with extra boli or a continuous infusion of remifentanil.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete